 
About the Program:
Program Overview:
The ARV Therapies and Therapeutic Strategies program is a comprehensive, independent review of the 23rd International AIDS Conference (AIDS 2020). This program consists of four components: (1) CME Internet Symposium: AIDS 2020 Expert Review: an Internet symposium that features an overview of key presentations and posters, selected by the expert faculty; (2) From Conference to Clinic**: Reviewing and Applying Data from AIDS 2020: a case-based on-line webcast featuring expert faculty reviewing key presentations with a focus on clinical management and treatment; (3) Rapid-Fire Review of AIDS 2020: a podcast that provides a brief, audio summary of the most essential data presented at the conference; and (4) AIDS 2020 e-Newsletter**: a brief on-line summary of the most essential data presented at the conference.
The Rapid-Fire Review of AIDS 2020 features
our national faculty panel briefly reviewing the most essential
information and data from AIDS 2020. This activity will enable
participating health care providers caring for HIV-infected patients to
become aware of and understand the data presented at this important
conference and appropriately utilize those data to improve patient care.
All online components of the program can be accessed at www.viraled.com
This
program is produced by the Postgraduate Institute for Medicine and
ViralEd, Inc. It is not a session created by or presented at AIDS 2020 and it is not sanctioned by the organizers of AIDS 2020.
**These components are jointly provided by the Annenberg Center for Health Sciences and ViralEd, Inc., in collaboration with Postgraduate Institute for Medicine and supported by an independent educational grant from Janssen Therapeutics, Division of Janssen Products LP.
Target Audience:
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.
Learning Objectives:
After completing this activity, the participant should be better able to:
- Apply in a clinical setting the most current HIV prevention and treatment approaches and paradigms
- Influence retention of patients on ARV therapy by addressing ARV side effects that can interfere with adherence to ARV regimens
- Employ the rapid initiation of appropriate and effective antiretroviral therapy
- Describe new antiretroviral agents in development and how they may be used in the treatment of people with HIV infection
Release Date: July 16, 2020
Expiration Date: July 16, 2021
Estimated time to complete the Podcast: 60 minutes
Media: Internet, Phone, Tablet
Faculty:
|
José Arribas, MD
Senior Attending Physician, HIV Unit
Hospital de La Paz
Madrid, Spain
|
Jürgen Rockstroh, MD
Professor of Medicine
Department of Medicine
University Hospital
Bonn, Germany
|
Marta Boffito, MD, PhD
St. Stephen's AIDS Trust and Imperial College
Chelsea and Westminster Hospital
London, United Kingdom
|
Paul Sax, MD
Clinical Director Division of Infectious Diseases
Brigham and Womens Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts |
Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research
Perelman School of Medicine
at the University of Pennsylvania
Philadelphia, Pennsylvania
|
Renslow Sherer, MD
Professor of Medicine,
Section of Infectious Diseases and Global Health,
University of Chicago
Chicago, Illinois |
Graeme Moyle, MD, MB, BS
Associate Director of HIV Research
Chelsea & Westminster Hospital
London, United Kingdom |
|
Joint Accreditation Statement:
 |
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
| The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. |
Disclosure of Conflicts of Interest:
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this
activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary
business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Jose Arribas, MD
- Consulting Fees: Janssen, MSD, ViiV, Alexa, Teva
Marta Boffito, MD
- Consulting Fees: Gilead, BMS, ViiV
- Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their agents (eg. speakers' bureaus): Gilead, Janssen, ViiV, BMS
- Contracted Research: Gilead, Janssen, ViiV, BMS
Ian Frank, MD
- Consulting Fees: Gilead, GSK
- Contracted Research: Johnson & Johnson
Graeme Moyle, MD
- Consulting Fees: Theratechnologies, Gilead, ViiV
- Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their agents (eg. speakers' bureaus): Theratechnologies, Gilead, ViiV
- Contracted Research (institution only): Amgen, Merck, Gilead, ViiV
Jürgen Rockstroh, MD
- Consulting Fees: Gilead, Merck, Janssen, Theratechnologies, ViiV
- Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their agents (eg. speakers' bureaus): Gilead, Merck, Janssen, ViiV
Paul Sax, MD
- Consulting Fees: Gilead, GSK/ViiV, Janssen, Merck
- Contracted Research: Gilead, GSK/ViiV, Merck
- Other (Editorial Boards): Medscape, UpToDate, NEJM Journal Watch, Open Forum ID
The PIM planners and managers have nothing to disclose.
Disclosure of Unlabeled Use:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planner. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and
warnings.
Instructions for Participation and Credit:
There are no fees for participating and receiving CME credit for this activity. During the period, July 16, 2020 through July 16, 2021, participants must read the learning objectives and faculty disclosures and study the educational activity.
PIM supports Green CME by offering your Request for Credit online. If you wish to received acknowledgment of completing this activity, please complete the evaluation on www.cmeuniveristy.com. On the navigation menu, click on "Find Post-test/Evaluation
by Course" and search by course ID 15228. Upon registering and successfully completing the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount
of paper used by nearly 100,000 sheets per year.
Disclaimer:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.
Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by
clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable
manufacturer’s product information, and comparison with recommendations of other authorities.
Supported by an independent educational grant from Gilead Sciences Medical Affairs.
This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at AIDS 2020 and it is not sanctioned by AIDS 2020.
|
